Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion

Stroke

Volumn 29, Issue 9, 1998, Pages 1952-1958

  Tatlisumak, Turgut ^a,b,c   Takano, Kentaro ^b,c   Carano, Richard A D ^d   Miller, Leonard P ^e   Foster, Alan C ^e   Fisher, Marc ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Med Ctr Ctrl Massachusetts Mem   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Worcester Polytechnic Institute   (United States)

^e Metabasis Therapeutics Inc   (United States)

Author keywords

Adenosine; Cerebral infarction; Cerebral ischemia, focal; Neuroprotection; Rats; Temperature

Indexed keywords

4 ANILINO 5 PHENYLPYRROLO[2,3 D]PYRIMIDINE 7 (5 DEOXYRIBOSIDE); ADENOSINE; ADENOSINE KINASE INHIBITOR; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN PROTECTION; BRAIN TEMPERATURE; CONTROLLED STUDY; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGICAL COMPLICATION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 0031692409     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.9.1952     Document Type: Article

References (62)

1. Miller LP, Hsu C. Therapeutic potential of adenosine receptor activation in ischemic brain injury. J Neurotrauma. 1992;9(suppl 2):S563- S577.
2. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev. 1992;4:346-369.
3. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol Sci. 1992;13: 439-445.
4. 3H] nitrobenzylthioinosine as markers of adenosine metabolism and transport in central purinergic systems. In: Williams M, ed. Adenosine and Adenosine Receptors. Clifton, NJ: Humana Press; 1990:225.
5. Van Wylen DG, Park TS, Rubio R, Berne RM. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischemia. J Cereb Blood Flow Metab. 1986;6:522-528.
6. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M. Nomenclature and classification of purinoceptors: a report from the IUPHAR subcommittee. Pharmacol Rev. 1994;46:143-156.
7. 3H] cyclohexyladenosine. J Neurosci. 1982; 2:1230-1241.
8. Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathisen J. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci. 1987;10:273-280.
9. 1 receptors in human brain: characterization and autoradiographic visualization. Neurosci Lett. 1986;65:127-132.
10. Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience. 1992;51:501-512.
11. Berne RM, Rubio R, Curnish RR. Release of adenosine from ischemic brain: effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ Res. 1974;35:262-271.
12. Hagberg H, Andersson P, Lacarewicz J, Jacobson I, Butcher S, Sandberg M. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J Neurochem. 1987;49:227-231.
13. Hillered L, Hallström A, Segersvard S, Persson L, Ungerstedt U. Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J Cereb Blood Flow Metab. 1989;9:607-616.
14. Sciotti V, Litchmore T, Van Wylen DL. Interstitial fluid (ISF) purine metabolite levels during and after cerebral ischemia. FASEB J. 1990;4: A1095. Abstract.
15. Lloyd HGE, Lindström K, Fredholm BB. Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation and energy depletion. Neurochem Int. 1993;23:173-185.
16. Meno JR, Ngai AC, Ibayashi S, Wynn HR. Adenosine release and changes in pial arteriolar diameter during transient cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 1991;11:986-993.
17. Dragunow M, Faull RLM. Neuroprotective effects of adenosine. Trends Pharmacol Sci. 1988;9:193-194.
18. Phillis JW. Adenosine in the control of the cerebral circulation. Cerebrovasc Brain Metab Rev. 1989;1:26-54.
19. Marangos PJ, Von Lubitz D, Daval JL, Decken J. Adenosine: its relevance to the treatment of brain ischemia and trauma. Prog Clin Biol Res. 1990;361:331-349.
20. Phillis JW, Walter GA, Simpson RE. Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycoformycin. J Neurochem. 1991;56: 644-650.
21. Pardridge WM, Yoshikawa T, Kang Y-S, Miller LP. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Ther. 1994;268:14-18.
22. Miller LP, Chiang PC, Carriedo S, Metzner K, Foster AC. The adenosine regulating agent GP-1-668 reduces infarct volume and neurological deficits in a rat model of focal stroke with reperfusion. Stroke. 1994; 25:264. Abstract.
23. Miller LP, Jelovich LA, Yao L, DaRe J, Ugarkar B, Foster AC. Pre-and peristroke treatment with the adenosine kinase inhibitor. 5′ deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci Lett. 1996; 220:73-76.
24. Pak MA, Haas HL, Decking UK, Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology. 1994;33:1049-1053.
25. Lloyd HGE, Fredholm BB. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int. 1995;26:387-395.
26. Mullane K, Bullough D, Shapiro D. From academic vision to clinical reality: a case of acadesine. Trends Cardiovasc Med. 1993;3:227-234.
27. Deleted in proof.
28. Erion MD, Ugarkar BG, DaRe J, Castellino AJ, Fujilaki JM, Dixon R, Appleman JR, Wiesner JB. Nucleosides, and Nucleotides. 16;1013-1021, 1997.
29. Wiesner JB, Zimring ST, Castellino AJ, Ugarkar B, Shea M, Erion MD, Foster AC. Anticonvulsant profile of a novel adenosine kinase inhibitor, GP683, in rodents. Epilepsia. 1995;36(suppl. 4):86. Abstract.
30. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20: 84-91.
31. Lin T-N, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal ischemia model in rats. Stroke. 1993;24: 117-121.
32. Li F, Irie K, Anwer MS, Fisher M. Delayed triphenyltetrazolium chloride staining remains useful for evaluating cerebral infarct volume in a rat stroke model. J Cereb Blood Flow Metab. 1997;17:1132-1135.
33. Cantor SL, Zornow MH, Miller LP, Yaksh TL. The effect of cyclohexyladenosine on the periischemic increases of hippocampal glutamate and glycine in the rabbit. J Neurochem. 1992;59:1884-1892.
34. Schubert P, Rudolphi KA, Fredholm BB, Nakamura Y. Modulation of nerve and glial function by adenosine-role in the development of ischemic damage. Int J Biochem. 1994;26:1227-1236.
35. Fredholm BB, Dunwiddie TU. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9:130-134.
36. Kauppinen RA, Enkvist K, Holopainen I, Åkerman KEO. Glucose deprivation depolarizes plasma membrane of cultured astrocytes and collapses transmembrane potassium and glutamate gradients. Neuroscience. 1988;26:283-289.
37. Bhardwaj A, Northington FJ, Koehler RC, Stiefel T, Hanley DF, Traystman RJ. Adenosine modulates N-methyl-D-aspartate-stimulated hippocampal nitric oxide production in vivo. Stroke. 1995;26: 1627-1633.
38. Sciotti VM, Roche FM, Grabb MC, Van Wylen DGL. Adenosine receptor blockade augments interstitial fluid levels of excitatory amino acids during cerebral ischemia. J Cereb Blood Flow Metab. 1992;12:646-655.
39. 1 agonist in rat hippocampal cells. Neurosurgery. 1995;36:1003-1007.
40. Hourani SMO, Cusack NJ. Pharmacological receptors on blood platelets. Pharmacol Rev. 1991;43:243-298.
41. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78:760-770.
42. 2 receptor on human neutrophils. J Immunol. 1985;135:1366-1371.
43. Collis MG. The vasodilator role of adenosine. Pharmacol Ther. 1989;42: 143-162.
44. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA. Adenosine-mediated inhibition of platelet aggregation by acadesine: a novel antithrombotic mechanism in vitro and in vivo. J Clin Invest. 1994;94: 1524-1532.
45. Dietrich WD, Miller LP, Prado R, Dewanjee S, Alexis N, Dewanjee MK, Gruber H. Acadesine reduces indium-labeled platelet deposition after photothrombosis of the common carotid artery in rats. Stroke. 1995;26:111-116.
46. Muhonen MG, Loftus CM, Heistad DD. Effects of adenosine and 2-chloroadenosine on cerebral collateral vessels. J Cereb Blood Flow Metab. 1995;15:1075-1081.
47. Goldberg MP, Monyer H, Weiss JH, Choi DW. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neurosci Lett. 1988;89:323-327.
48. 3 receptor stimulation and cerebral ischemia. Eur J Pharmacol. 1994;263:59-67.
49. Grant GA, Meno JR, Winn R, Janigro D. Adenosine reduces L-aspartate transport across the blood-brain barrier: a mechanism for neuroprotection? Stroke. 1998;29:324. Abstract.
50. Phillis JW, Smith-Barbour M. The adenosine kinase inhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci. 1993;53:497-502.
51. Sciotti VM, Van Wylen DG. Increase in interstitial adenosine and cerebral blood flow with inhibition of adenosine kinase and adenosine deaminase. J Cereb Blood Flow Metab. 1993;13:201-207.
52. Rosengren S, Bong GW, Firestein GS. Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J Immunol. 1995;154:5444-5451.
53. Cronstein BN, Naime D, Firestein GS. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum. 1995;38:1040-1045.
54. Firestein GS, Bullough DA, Erion MD, Jimenez R, Ramirez-Weinhouse M, Barankiewicz J, Smith CW, Gruber HE, Mullane KM. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: the role of selectins. J Immunol. 1995;154:326-334.
55. Pazzagli M, Corsi C, Fratti S, Pedata F, Pepeu G. Regulation of extracellular adenosine levels in the striatum of aging rats. Brain Res. 1995; 684:103-106.
56. Fredholm BB, Lloyd HG. Sources of adenosine released from hippocampal slices following electrical and hypoxic hypoglycemic stimulation. Ann N Y Acad Sci. 1990;603:497-499.
57. White TD. Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. Eur J Pharmacol. 1996;303:27-38.
58. Davies LP, Cook AF. Inhibition of adenosine kinase and adenosine uptake in guinea-pig CNS tissue by halogenated tubercidin analogues. Life Sci. 1995;56:345-359.
59. Phillis JW, O'Regan MH. Effects of an inhibitor of adenosine deaminase, deoxycoformycin, and of nucleoside transport, propentofylline, on post-ischemic recovery of adenosine nucleotides in rat brain. Neurochem Res. 1996;21:347-353.
60. Vibulsresth S, Dietrich WD, Busto R, Ginsberg MD. Failure of nimodipine to prevent ischemic neuronal damage in rats. Stroke. 1987;18:210-216.
61. Globus MY-T, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Intra-ischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia. Neurosci Lett. 1988;91:36-40.
62. Busto R, Dietrich WD, Globus MY-T, Ginsberg MD. The importance of brain temperature in cerebral ischemic injury. Stroke. 1989;20: 1113-1114.